COVID-19 & FLU EXPRESS



COVID-19 & Flu Express is a weekly report produced by Surveillance Division of the Communicable Disease Branch of the Centre for Health Protection. It monitors and summarizes the latest local and global COVID-19 and influenza activities.

Local Situation of COVID-19 Activity (as of Nov 27, 2024)

Reporting period: Nov 17 - Nov 23, 2024 (Week 47)

- The latest surveillance data showed that the overall local activity of COVID-19 remains at a low level.
- The Centre for Health Protection (CHP) has been closely monitoring the local prevalence of SAR-CoV-2 variants based on the World Health Organization (WHO)'s Tracking SAR-CoV-2 Variants list. The latest surveillance data showed that JN.1 is the most prevalent variant. At the same time, KP.2 and KP.3 are also detected in the sewage surveillance and human infection cases. However, the current information does not suggest JN.1 or KP.2 or KP.3 will cause a more severe disease than the previous prevalent XBB and its descendant lineages.
- Members of the public are advised to maintain strict personal and environmental hygiene at all times for personal protection against COVID-19 infection and prevention of the spread of the disease in the community. High risk people (e.g. persons with underlying medical conditions or persons who are immunocompromised) should adopt additional measures to protect themselves such as wearing mask properly when going to public places. For other details, please visit the COVID-19 information page (https://www.chp.gov.hk/en/healthtopics/content/24/102466.html).
- Members of the public are advised to take note of the latest recommendations on the use of COVID-19 vaccines in Hong Kong to protect themselves from serious outcomes of COVID-19. High-risk priority groups are recommended to receive a dose of COVID-19 vaccine at least six months since the last dose or infection, regardless of the number of doses received previously. For more details, please visit (https://www.chp.gov.hk/files/pdf/consensus interim recommendations on use of covid19 vaccines in hong kong 17jul.pdf).
- For the latest information on COVID-19 and prevention measures, please visit the thematic website of COVID-19 (https://www.coronavirus.gov.hk/eng/index.html).

Laboratory surveillance for COVID-19 cases

<u>Positive nucleic acid test laboratory detections for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus</u>

In week 47, the weekly number of newly recorded positive nucleic acid test laboratory detections for SARS-CoV-2 virus was 23 as compared to 26 in the preceding week. (Figure 1.1)

In the first 4 days of week 48 (Nov 24 – Nov 27), the daily number of newly recorded positive nucleic acid test laboratory detections for SARS-CoV-2 virus ranged from 3 to 6.

Since Jan 30, 2023, the cumulative number of positive nucleic acid test laboratory detections was 74,366 (as of Nov 27, 2024).




Figure 1.1 Weekly number of positive nucleic acid test laboratory detections for SARS-CoV-2 virus

Positive detection rate of specimens tested positive for SARS-CoV-2 virus at the Public Health Laboratory Services Branch

Among the 6,825 respiratory specimens received by the Public Health Laboratory Services Branch (PHLSB) in week 47, 31 (0.45%) were tested positive for SARS-CoV-2 virus as compared to 32 (0.46%) in the preceding week. (Figure 1.2)




Figure 1.2 Percentage of specimens tested positive for SARS-CoV-2 virus at PHLSB

COVID-19 outbreak surveillance

In week 47, 0 COVID-19 outbreak occurring in schools/institutions was recorded (affecting 0 person), as compared to 0 outbreak recorded in the previous week (affecting 0 person). (Figure 1.3)

In the first 4 days of week 48 (Nov 24 – Nov 27), 0 COVID-19 outbreak occurring in schools/institutions was recorded (affecting 0 person).




Figure 1.3 COVID-19 outbreaks in schools/institutions

Type of institutions	Week 46	Week 47	First 4 days of week 48 (Nov 24 – Nov 27)
Child care centre/ kindergarten (CCC/KG)	0	0	0
Primary school (PS)	0	0	0
Secondary school (SS)	0	0	0
Residential care home for the elderly	0	0	0
Residential care home for persons with disabilities	0	0	0
Others	0	0	0
Total number of outbreaks	0	0	0
Total number of persons affected	0	0	0

Surveillance of severe and fatal COVID-19 cases

(Note: The data reported are provisional figures and subject to further revision.)

In week 47, the weekly number of severe COVID-19 cases including deaths with cause of death preliminarily assessed to be related to COVID-19 was 1 as compared to 4 in the preceding week. (Figure 1.4)

Since Jan 30, 2023, the cumulative number of fatal cases with cause of death preliminarily assessed to be related to COVID-19 was 1,395 (as of Nov 23, 2024).




Figure 1.4 Weekly number of severe COVID-19 cases including deaths

Note: Severe and fatal cases are recorded according to their initial reporting dates.

Sewage surveillance of SARS-CoV-2 virus

In week 47, the 7-day geometric mean per capita viral load of SARS-CoV-2 virus from sewage surveillance was around 21,000 copy/L as compared to around 25,000 copy/L in the preceding week. (Figure 1.5)




Figure 1.5 7-day geometric mean per capita viral load of SARS-CoV-2 virus from sewage surveillance since May 1, 2022

Note: The dotted line refers to the temporary sewage sampling suspension for a safety review by the Drainage Services Department.

COVID-19 surveillance among sentinel general out-patient clinics and sentinel private medical practitioner clinics

In week 47, the average consultation rate for COVID-19 among sentinel general out-patient clinics (GOPC) and sentinel private medical practitioner clinics were 1.4 (Figure 1.6) and 1.5 (Figure 1.7) COVID-19 cases per 1,000 consultations, respectively.




Figure 1.6 Average consultation rate of COVID-19 cases in GOPC




Figure 1.7 Average consultation rate of COVID-19 cases in private medical practitioner clinics

Surveillance on SARS-CoV-2 variants

CHP conducts surveillance on SARS-CoV-2 variants from sewage samples. The latest surveillance data (as of Nov 27, 2024) showed that JN.1 and its descendant lineages remained the most prevalent variant, comprising over 94% of all characterised specimens, where 48.8% belongs to the descendant strain KP.3, 12.7% to KP.2 and 10.3% to KP.3.1.1. (Figure 1.8)




Figure 1.8 Estimated proportion of variants among sewage samples

 $[^]st$ Including JN.1 and its descendant lineages, except those individually specified elsewhere in the table

^{*}Those SARS-CoV-2 variants not classified as variants of interest (VOIs)/ variants under monitoring (VUMs) by WHO Note: JN.1.7, JN.1.18, KP.2, KP.3, KP.3.1.1, LB.1 and XEC are the descendant lineages of JN.1

CHP also conducted genetic characterisation on 3 specimens obtained from reported severe and fatal cases of COVID-19 between Nov 6 and Nov 19, 2024. The results showed that JN.1 and its descendant lineages remained the most prevalent variant, comprising 100% of all characterised specimens, of which 66.7% (2 cases) belonged to the descendant strain KP.3. (Figure 1.9)




Figure 1.9 Proportion of variants among specimens obtained from reported severe and death cases for COVID-19
*Including JN.1 and its descendant lineages, except those individually specified elsewhere in the table

Besides, CHP conducted genetic characterisation for the specimens obtained from some non-severe cases of COVID-19 during the same period. The results showed that JN.1 and its descendant lineages remained the most prevalent variant, comprising 100% of all characterised specimens, of which 6.1% belonged to the descendant lineage KP.2 and 30.3% belonged to the descendant lineage KP.3.

[#]Those SARS-CoV-2 variants not classified as VOIs/ VUMs by WHO

Global situation of COVID-19 activity

- Globally, as of Nov 10, 2024, there have been 776,841,264 confirmed cases of COVID-19, including 7,075,468 deaths, reported to WHO.
- According to WHO COVID-19 epidemiological update last published on Nov 6, 2024,
 - Over 320,000 new cases and more than 4,500 new deaths were reported in the last 28 days (Sep 16 to Oct 13, 2024) globally.
 - ◆ The highest numbers of new 28-day cases were reported from Russia, Poland, Czechia, Greece, and the UK. The highest numbers of new 28-day deaths were reported from the USA, Sweden, Russia, Greece, Czechia, and Denmark.
 - ◆ WHO commented that current trends in reported COVID-19 cases were underestimates of the true number due to the reduction in testing and delays in reporting in many countries. Therefore, related data should be interpreted with caution.
 - ◆ Currently, WHO is monitoring two VOIs, which are BA.2.86 and JN.1, and seven VUMs, which are JN.1.7, JN.1.18, KP.2, KP.3, KP.3.1.1, LB.1 and XEC.
 - ◆ Between Oct 7 and Oct 13, 2024, JN.1 is the most reported VOI globally, accounting for 12.2% and having declined from a prevalence of 17.2% between Sep 16 and Sep 22, 2024. The risk evaluation for JN.1 published on Apr 15, 2024 suggests an overall low public health risk at the global level based on available evidence. During the same period, the prevalence of BA.2.86 decreased from 0.2% to 0%. Among the VUMs, the prevalence of two variants showed increasing trends, including KP.3.1.1 (45.2% to 51.1%) and XEC (8.9% to 17.2%). JN.1.18 remained stable between 1.4% and 2.1%. Meanwhile, the prevalence of the other four VUMs were declining, including KP.3 (13.0% to 10.9%), KP.2 (7.0% to 2.9%), LB.1 (4.6% to 1.7%) and JN.1.7 (0.1% to 0%).

Sources:

- 1. WHO COVID-19 dashboard, accessed on Nov 28, 2024
- 2. Tracking SARS-CoV-2 variants
- 3. World Health Organization COVID-19 epidemiological update

Local Situation of Influenza Activity (as of Nov 27, 2024)

Reporting period: Nov 17 - 23, 2024 (Week 47)

- The latest surveillance data showed that the overall influenza activity remained low.
- Influenza can cause serious illnesses in high-risk individuals and even healthy persons. Given that
 seasonal influenza vaccines are safe and effective, all persons aged 6 months or above except
 those with known contraindications are recommended to receive influenza vaccine to protect
 themselves against seasonal influenza and its complications, as well as related hospitalisations
 and deaths.
- 2024/25 Seasonal Influenza Vaccination Programmes, including the Seasonal Influenza Vaccination School Outreach Programme and the Residential Care Home Vaccination Programme (RVP), has been launched on September 26, 2024. The public may visit the CHP's Vaccination Schemes page for more details of the vaccination programmes (https://www.chp.gov.hk/en/features/17980.html).
- Apart from getting influenza vaccination, members of the public should always maintain good personal and environmental hygiene.
- For the latest information on seasonal influenza and its prevention, please visit the Centre for Health Protection's Seasonal Influenza page
 - (http://www.chp.gov.hk/en/view content/14843.html).

Influenza-like-illness surveillance among sentinel general out-patient clinics and sentinel private medical practitioner clinics, 2020-24

In week 47, the average consultation rate for influenza-like illness (ILI) among sentinel general outpatient clinics (GOPC) was 3.5 ILI cases per 1,000 consultations, which was higher than 3.2 recorded in the previous week (Figure 2.1, left). The average consultation rate for ILI among sentinel private medical practitioner (PMP) clinics was 32.4 ILI cases per 1,000 consultations, which was lower than 33.9 recorded in the previous week (Figure 2.1, right).




Figure 2.1 ILI consultation rates at sentinel GOPC (left) and PMP clinics (right), 2020-24

Note: The CHP has started to use electronic data on diagnosis coding of patients of the Hospital Authority's GOPC for sentinel surveillance since January 2020, replacing manual data collection in the past.

Laboratory surveillance, 2020-24

Among the 7,241 respiratory specimens* received in week 47, 59 (0.81%) were tested positive for seasonal influenza A or B viruses. Among the subtyped influenza detections, there were 32 (59%) influenza A(H1), 9 (17%) influenza A(H3) and 13 (24%) influenza B viruses. The positive percentage (0.81%) was below the baseline threshold of 9.21% but was higher than 0.52% recorded in the previous week (Figure 2.2).




Figure 2.2 Percentage of respiratory specimens tested positive for influenza viruses, 2020-24 (upper: overall positive percentage, lower: positive percentage by subtypes)

[Note: The baseline threshold is 1.96 standard deviation above the average weekly positive percentage during non-season periods from 2014 week 49 to 2019 week 48.]

Remarks: Some specimens may contain vaccine strains from people with recent history of receiving live-attenuated influenza vaccine

Surveillance of oseltamivir resistant influenza A and B viruses

- In October 2024, there were no new reports of oseltamivir (Tamiflu) resistant influenza A and B viruses.
- For the results of previous months, please refer to the following webpage: https://www.chp.gov.hk/en/statistics/data/10/641/695/7068.html

^{*} Including 6,825 specimens received by Public Health Laboratory Services Branch, Centre for Health Protection and 416 specimens received by the Hospital Authority

Influenza-like illness outbreak surveillance, 2020-24

In week 47, 4 ILI outbreaks occurring in schools/institutions were recorded (affecting 16 persons), as compared to 2 outbreak recorded in the previous week (affecting 11 persons) (Figure 2.3). In the first 4 days of week 48 (Nov 24 to 27), 6 ILI outbreaks in schools/institutions were recorded (affecting 23 persons).




Figure 2.3 ILI outbreaks in schools/institutions, 2020-24

Type of institutions	Week 46	Week 47	First 4 days of week 48 (Nov 24 – 27)
Child care centre/ kindergarten (CCC/KG)	0	1	1
Primary school (PS)	2	1	3
Secondary school (SS)	0	1	0
Residential care home for the elderly	0	1	2
Residential care home for persons with disabilities	0	0	0
Others	1	0	0
Total number of outbreaks	2	4	6
Total number of persons affected	11	16	23

Influenza-associated hospital admission rates in public hospitals based on discharge coding, 2020-24

In week 47, the overall admission rates in public hospitals with principal diagnosis of influenza was 0.03 (per 10,000 population), which was below the baseline threshold of 0.25 but was higher than 0.02 recorded in the previous week. The influenza-associated admission rates for persons aged 0-5 years, 6-11 years, 12-17 years, 18-49 years, 50-64 years and 65 years or above were 0.08, 0.06, 0.03, 0.01, 0.02 and 0.06 cases (per 10,000 people in the age group) respectively, as compared to 0.17, 0.03, 0.03, 0.02, 0.01 and 0.02 cases in the previous week (Figure 2.4).




Figure 2.4 Influenza-associated hospital admission rates, 2020-24 (upper: overall rate, lower: rates by age groups)
[Note: The baseline threshold is 1.96 standard deviation above the average weekly admission rate during non-season periods from 2014 week 49 to 2019 week 48.]

Rate of ILI syndrome group in accident and emergency departments, 2020-24#

In week 47, the rate of the ILI syndrome group in the accident and emergency departments (AEDs) was 116.5 (per 1,000 coded cases), which was lower than the rate of 126.8 in the previous week (Figure 2.5).

#Note: This syndrome group includes codes related to ILI such as influenza, upper respiratory tract infection, fever, cough, throat pain, and pneumonia.




Figure 2.5 Rate of ILI syndrome group in AEDs, 2020-24

Fever surveillance at sentinel residential care homes for the elderly, 2020-24

In week 47, 0.08% of residents in the sentinel residential care homes for the elderly (RCHEs) had fever (38°C or above), compared to 0.08% recorded in the previous week (Figure 2.7).




Figure 2.7 Percentage of residents with fever at sentinel RCHEs, 2020-24

Fever surveillance at sentinel child care centres/ kindergartens, 2020-24

In week 47, 0.67% of children in the sentinel child care centres / kindergartens (CCCs/KGs) had fever (38°C or above) as compared to 0.84% recorded in the previous week (Figure 2.6).




Figure 2.6 Percentage of children with fever at sentinel CCCs/KGs, 2020-24

Influenza-like illness surveillance among sentinel Chinese medicine practitioners, 2020-24

In week 47, the average consultation rate for ILI among Chinese medicine practitioners (CMPs) was 0.63 ILI cases per 1,000 consultations as compared to 0.45 recorded in the previous week (Figure 2.8).




Figure 2.8 ILI consultation rate at sentinel CMPs, 2020-24

Surveillance of severe influenza cases

(Note: The data reported are provisional figures and subject to further revision.)

<u>Surveillance for intensive care unit (ICU) admission/death with laboratory confirmation of influenza among adult patients (Aged 18 years or above)</u>

Since 2018, the Centre for Health Protection (CHP) has collaborated with the Hospital Authority and private hospitals to monitor ICU admissions and deaths with laboratory confirmation of influenza among adult patients regularly. For surveillance purpose, the cases refer to laboratory-confirmed influenza patients who required ICU admission or died within the same admission of influenza infection. Their causes of ICU admission or death may be due to other acute medical conditions or underlying diseases.

• In week 47, 3 adult cases of ICU admission/death with laboratory confirmation of influenza (including 3 deaths) were recorded, as compared to 3 cases (including 1 death) in the previous week.

Week	Influenza type			
	A(H1)	A(H3)	В	A (pending subtype)
Week 46	1	0	2	0
Week 47	2	0	0	1

<u>Surveillance of severe paediatric influenza-associated complication/death (Aged below 18 years)</u>

- In week 47 and the first 4 days of week 48 (Nov 24 to 27), there were no cases of severe paediatric influenza-associated complication/death.
- In 2024, 35 paediatric cases of severe influenza-associated complication/death were recorded, in which six of them were fatal (as of Nov 27, 2024).




Figure 2.9 Weekly number of severe influenza cases by age groups, 2020-24 (the percentage positive for influenza viruses in Figure 2.2 is also shown in this graph)

Global Situation of Influenza Activity

In the Northern hemisphere, influenza activity in temperate countries remained at interepidemic levels. Influenza A viruses predominated in South East Asia. In the Southern Hemisphere, influenza activity in most countries remained similar or declined (data up to Nov 10, 2024).

- In the United States (week ending Nov 16, 2024), influenza activity increased slightly among children but remained low nationally. The percentage of specimens tested positive for influenza was 2.1%.
- In Canada (week ending Nov 16, 2024), indicators of influenza activity were stable and remained at interseasonal levels. The weekly percentage of tests positive for influenza was 0.9% in week 46.
- In the United Kingdom (week ending Nov 17, 2024), influenza activity increased across some indicators but remained within baseline levels. Influenza positivity in England increased to 3.9% as compared with 3.3% in preceding week.
- In Europe (week ending Nov 17, 2024), influenza activity remained below the 10% positivity epidemic threshold at 3%.
- In Mainland China (week ending Nov 17, 2024), influenza surveillance data showed the
 percentage of specimens tested positive for influenza in southern and northern provinces slightly
 increased, with 5.4% and 3.6% in week 46 respectively. Influenza A(H1N1)pdm09 viruses
 predominated.
- In Japan (week ending Nov 17, 2024), the average number of reported ILI cases per sentinel site increased to 1.88 from 1.06 in the preceding week, and was above the baseline level of 1.00. Most of the influenza detections in recent weeks were influenza A(H1N1)pdm09 viruses.
- In Australia (fortnight ending Oct 20, 2024), influenza activity has decreased considerably since July, and has now returned to interseasonal level.
- In New Zealand (week ending Oct 27, 2024), influenza detections in community and hospital settings are now at low inter-seasonal levels.

Sources:

Information have been extracted from the following sources when updates are available: World Health Organization, United States Centers for Disease Control and Prevention, Public Health Agency of Canada, UK Health Security Agency, European Centre for Disease Prevention and Control (ECDC) and WHO Regional Office for Europe (WHO Euro), Chinese National Influenza Center, Japan Ministry of Health, Australian Department of Health and Aged Care and New Zealand Ministry of Health.